Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prediabetes Market

Prediabetes Market Analysis

  • Report ID: GMI8874
  • Published Date: Apr 2024
  • Report Format: PDF

Prediabetes Market Analysis

Based on drug class, the market is segmented into biguanides, thiazolidinediones, glucagon-like peptide-1 agonists (GLP-1), sodium-glucose cotransporter 2 inhibitors (SGLT2), dipeptidyl peptidase-4 inhibitors (DPP-4), and other drug classes. The biguanides segment is estimated to account for USD 254.6 million by the end of 2032.

  • Metformin, a commonly prescribed biguanides, effectively lowers blood sugar levels by reducing glucose production in the liver and improving insulin sensitivity. With the escalating prevalence of prediabetes due to factors such as obesity and sedentary lifestyles, there is a growing demand for pharmacological interventions, aligning with clinical guidelines recommending metformin as a first-line treatment.
  • Additionally, ongoing research and development efforts aimed at enhancing biguanides medications' efficacy and safety, coupled with their cost-effectiveness compared to other treatments, further bolster their market potential.
Prediabetes Market, By Age Group (2023)

Based on age group, the prediabetes market is segmented into children (12-18 years), adults (18-49), and elderly (50+). The adults (18-49) segment held a substantial revenue of USD 92.7 million in 2023.

  • The rising prevalence of prediabetes within this demographic, attributed to lifestyle-related risk factors, contributes to increased diagnosis and treatment demand.
  • Heightened awareness campaigns and proactive screening initiatives by healthcare providers further amplify detection rates. Additionally, the market benefits from continuous innovation, with pharmaceutical companies developing tailored interventions and digital health solutions for this age group.
  • Lifestyle factors such as poor diet and sedentary habits make adults aged 18-49 particularly susceptible, necessitating interventions to manage prediabetes effectively. Improvements in healthcare infrastructure and enhanced access to care also play a crucial role in propelling the market growth by facilitating timely diagnosis and treatment.

Based on distribution channel, the prediabetes market is segmented into wholesalers/distributors, retail chain, online distribution, and other distribution channels. The wholesalers/distributors segment held a substantial revenue of USD 126.8 million in 2023.

  • Wholesalers and distributors possess expansive distribution networks, enabling them to reach various healthcare facilities, pharmacies, and retail outlets efficiently.
  • Their ability to purchase products in bulk at discounted rates ensures favorable profit margins. Additionally, skilled management of logistics and supply chains ensures timely delivery and continuous availability of prediabetes-related products.
  • Strong relationships with manufacturers afford them preferential treatment and access to new innovations, further bolstering their competitive edge.
  • Value-added services, compliance with regulatory standards, and the burgeoning market demand for prediabetes solutions all contribute to the segment's notable revenue within the market.
North America Prediabetes Market, 2021 – 2032 (USD Million)

In 2023, North America held a significant market share of 40.7% in the prediabetes market and is predicted to witness substantial market growth over the analysis timeline.

  • North America boasts advanced healthcare infrastructure and robust research and development capabilities, fostering innovation in prediabetes detection, management, and treatment.
  • Increasing awareness among healthcare professionals and the general population about the risks associated with prediabetes has led to higher diagnosis rates and proactive management strategies, stimulating the market growth.
  • Moreover, the region's growing aging population, coupled with sedentary lifestyles and unhealthy dietary habits, has contributed to a rise in prediabetes prevalence, further fueling market expansion.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prediabetes industry size recorded USD 198.4 million in 2023 and will grow at a 6.9% CAGR between 2024 and 2032 owing to rise in obesity rates and sedentary lifestyles, emphasis on preventive healthcare measures and investments in screening programs.

The biguanides segment in the prediabetes industry will register USD 254.6 million by 2032, attributed to the effectiveness and widespread use of biguanides, such as metformin, as a first-line treatment for prediabetes.

North America prediabetes industry captured 40.7% revenue share in 2023, driven by high prevalence of prediabetes in the region, rising obesity rates, and sedentary lifestyles.

Prominent prediabetes firms are Abbott Laboratories, AstraZeneca PLC, CH Boehringer Sohn AG & Co KG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.

Prediabetes Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 217
  • Countries covered: 22
  • Pages: 167
 Download Free Sample